Farmácia/Notícias da Indústria

[Comunicado de imprensa – ainda não publicado] Um estudo de fase 3, com mais de 10.000 participantes, mostrou que a dose de reforço com a vacina da Pfizer/BioNTech teve eficácia de 95,6% contra Covid-19; houve 5 casos de doença no grupo com dose de reforço e 109 casos no grupo-controle, sem classificação quanto à gravidade da doença.

22 Out, 2021 | 12:31h

Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine

Comentário: Booster dose of Pfizer/BioNTech coronavirus vaccine shows 95.6% efficacy in Phase 3 trial, companies say – CNN

Comentários no Twitter

This will presumably mean everyone gets boosters early next year. That’s great, because they do work. Except it’s likely to be boosters for rich countries at the expense of primary vaccination for poorer countries. You won’t stop the pandemic when half the world is unvaccinated https://t.co/F31DMSI2zf

— Niall Conroy (@NICU_doc_salone) October 21, 2021

The 1st randomized trial of a booster (3rd) shot in 10,000 people, placebo-controlled, shows 95.6% efficacy, with 5 cases (Pfizer vaccine) vs 109 in placebo group, Delta variant, broad benefit across age groups https://t.co/TQpF35d8Jk pic.twitter.com/3RkqvXNfsU

— Eric Topol (@EricTopol) October 21, 2021

Estudo randomizado | Mirtazapina não é melhor que placebo para tratar a agitação em pessoas com demência e possivelmente esteve associada a mortalidade aumentada (7 mortes vs. 1, diferença não estatisticamente significativa, p = 0,065).

22 Out, 2021 | 12:17h

Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial – The Lancet

Comentário: Common antidepressant should no longer be used to treat people with dementia – University of Exeter

Vacina da Pfizer mostrou efetividade estimada de 93% contra infecção sintomática pela variante Delta do SARS-CoV-2 em adolescentes.

21 Out, 2021 | 11:37h

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents – New England Journal of Medicine

Conteúdo relacionado: CDC Study: Pfizer vaccine showed 93% effectiveness against Covid-19 hospitalization among children aged 12-18 years.

Comentário no Twitter

The remarkably high effectiveness (VE) of vaccination for teens vs the Delta variant in over 94,000 vaccinees and 94,000 matched controls: 93% VE vs symptomatic infection (95% CI 88,97) https://t.co/wwoXlw7PH9 @NEJM pic.twitter.com/8m3fJ7avc5

— Eric Topol (@EricTopol) October 20, 2021

Uma análise da mortalidade de 114.000 pessoas infectadas pelo SARS-CoV-2 na Escócia revelou que a efetividade da vacina contra morte pela variante Delta foi de 90% para a Pfizer e 91% para a AstraZeneca.

21 Out, 2021 | 11:35h

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant – New England Journal of Medicine

Um estudo de caso-controle mostrou que a vacinação contra Covid-19 no início da gestação não esteve associada a risco aumentado de aborto no primeiro trimestre.

21 Out, 2021 | 11:34h

Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage – New England Journal of Medicine

Conteúdos relacionados:

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

FDA autoriza o uso de doses de reforço das vacinas da Moderna e da Johnson & Johnson, e afirma que misturar e combinar é OK.

21 Out, 2021 | 11:29h

FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK – CNN

Ver também:

FDA OKs mixing COVID vaccines; backs Moderna, J&J boosters – Associated Press

FDA OKs Moderna, J&J boosters, along with ‘mix and match’ approach – NBC News

Diretriz NCCN | Doença tromboembólica venosa associada a câncer.

21 Out, 2021 | 11:25h

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Conteúdos relacionados:

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

Systematic Review: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness?

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

O International Cannabis Toolkit (iCannToolkit): um consenso multidisciplinar de especialistas sobre os padrões mínimos para medir o uso de cannabis.

21 Out, 2021 | 11:13h

The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use – Addiction

Comentário: How to measure cannabis use: introducing the ‘International Cannabis Toolkit’ or iCannToolkit – The Mental Elf

Estudo randomizado | Nivolumabe vs. placebo em pacientes com mesotelioma maligno recidivante.

21 Out, 2021 | 11:10h

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial – The Lancet Oncology

Comentário no Twitter

CONFIRM Trial: a phase III study demonstrated longer PFS and OS with Nivolumab compared with Placebo in patients with Pleural or Peritoneal Malignant Mesothelioma who have progressed following platinum-based chemotherapy @OncoAlert #LCSM https://t.co/jKoKXEXgpB

— Dipesh Uprety MD FACP (@dipeshuprety4) October 15, 2021

Estudo do CDC | Vacina da Pfizer mostrou 93% de efetividade contra internações por Covid-19 entre crianças de 12 a 18 anos.

20 Out, 2021 | 12:12h

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 – CDC Morbidity and Mortality Weekly Report

Comentário no Twitter (fio – clique para saber mais)

Vaccination reduced the risk of hospitalization among 12–18-year-olds by 93%, according to a new CDC study. No vaccinated adolescents died or were admitted to the ICU.

— Dr. Tom Frieden (@DrTomFrieden) October 19, 2021